Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2002

01-04-2002 | Original Article

Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer

Authors: Muthukumaran Sivanandham, Christos I. Stavropoulos, Eugene M. Kim, Brian Mancke, Marc K. Wallack

Published in: Cancer Immunology, Immunotherapy | Issue 2/2002

Login to get access
Metadata
Title
Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer
Authors
Muthukumaran Sivanandham
Christos I. Stavropoulos
Eugene M. Kim
Brian Mancke
Marc K. Wallack
Publication date
01-04-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-001-0256-0

Other articles of this Issue 2/2002

Cancer Immunology, Immunotherapy 2/2002 Go to the issue

Original Article

Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen

Original Article

Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy

Original Article

Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma

Original Article

Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface

Original Article

Cloning, isolation and characterization of human tumor in situ monoclonal antibodies

Original Article

Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits